SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS (PSA) THROUGH 3 YEARS: EFFICACY AND SAFETY RESULTS FROM A PHASE 3 TRIAL
Hall S, Mease P, Kavanaugh A, Reimold A, Tahir H, Rech J, Geusens P, Pascale P, Delicha E, Pricop L, Mpofu S (2017)
Publication Type: Conference contribution
Publication year: 2017
Journal
Book Volume: 47
Pages Range: 37-38
Authors with CRIS profile
Involved external institutions
Hasselt University / Universiteit Hasselt
Belgium (BE)
Monash University
Australia (AU)
Barts Health NHS Trust
United Kingdom (GB)
Dallas VA Medical Center
United States (USA) (US)
Swedish Medical Center
United States (USA) (US)
University of California, San Diego
United States (USA) (US)
Novartis AG
Switzerland (CH)
Belgium (BE)
Monash University
Australia (AU)
Barts Health NHS Trust
United Kingdom (GB)
Dallas VA Medical Center
United States (USA) (US)
Swedish Medical Center
United States (USA) (US)
University of California, San Diego
United States (USA) (US)
Novartis AG
Switzerland (CH)
How to cite
APA:
Hall, S., Mease, P., Kavanaugh, A., Reimold, A., Tahir, H., Rech, J.,... Mpofu, S. (2017). SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS (PSA) THROUGH 3 YEARS: EFFICACY AND SAFETY RESULTS FROM A PHASE 3 TRIAL. (pp. 37-38).
MLA:
Hall, S., et al. "SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS (PSA) THROUGH 3 YEARS: EFFICACY AND SAFETY RESULTS FROM A PHASE 3 TRIAL." 2017. 37-38.
BibTeX: Download